Retatrutide (LY3437943) is an investigational peptide developed as an agonist of three metabolically relevant receptor systems: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).
This triple-receptor profile distinguishes retatrutide from single-receptor GLP-1 agonists and dual GIP/GLP-1 receptor agonists. Retatrutide has been evaluated in clinical research involving obesity, type 2 diabetes, and related metabolic conditions.
This reference is intended to provide researchers with an overview of retatrutide nomenclature, receptor classification, molecular characteristics, analytical identification, and published research.
Research information only. Retatrutide remains an investigational compound and is not represented here as an FDA-approved drug.
Retatrutide Quick Reference
| Compound | Retatrutide |
| Development Name | LY3437943 |
| CAS Number | 2381089-83-2 |
| Compound Type | Peptide-based triple receptor agonist |
| Primary Receptor Classification | GIPR / GLP-1R / GCGR agonist |
| Research Status | Investigational / clinical development |
What Is Retatrutide?
Retatrutide is an investigational peptide designed to activate the GIP, GLP-1, and glucagon receptors within a single molecule.
The compound was originally studied under the development identifier LY3437943. Its multi-receptor profile has made it an important research subject in the study of metabolic signaling, incretin biology, glucose regulation, energy balance, and related physiological pathways.
Retatrutide differs mechanistically from compounds that primarily activate the GLP-1 receptor alone and from dual-receptor compounds that target GIP and GLP-1 receptors.
Retatrutide Receptor Activity
The defining characteristic of retatrutide is its activity across three receptor systems.
GIP Receptor (GIPR)
Glucose-dependent insulinotropic polypeptide, commonly abbreviated GIP, is an incretin hormone involved in metabolic and nutrient-responsive signaling. Retatrutide incorporates GIP receptor agonism as one component of its multi-receptor activity.
GLP-1 Receptor (GLP-1R)
Glucagon-like peptide-1 receptor signaling is extensively studied in endocrine and metabolic research. GLP-1 receptor activity forms another component of retatrutide's receptor profile.
Glucagon Receptor (GCGR)
Retatrutide also incorporates glucagon receptor agonism. This third receptor target is one of the primary characteristics distinguishing retatrutide from dual GIP/GLP-1 receptor agonists.
Retatrutide vs. Semaglutide vs. Tirzepatide
Semaglutide, tirzepatide, and retatrutide are frequently discussed together because each interacts with incretin-related receptor systems, but their receptor profiles are not identical.
| Compound | GLP-1R | GIPR | GCGR | General Research Classification |
|---|---|---|---|---|
| Semaglutide | Yes | No | No | GLP-1 receptor agonist |
| Tirzepatide | Yes | Yes | No | Dual GIP/GLP-1 receptor agonist |
| Retatrutide | Yes | Yes | Yes | Triple GIP/GLP-1/glucagon receptor agonist |
The addition of glucagon receptor activity gives retatrutide a distinct receptor profile compared with semaglutide and tirzepatide.
Read: Retatrutide vs. Tirzepatide Research Comparison
Read: Semaglutide vs. Tirzepatide vs. Retatrutide
Retatrutide Molecular and Structural Research
Retatrutide is a modified peptide engineered to interact with multiple metabolically relevant receptors. Its structural design supports activity across the GIP, GLP-1, and glucagon receptor systems rather than focusing on a single receptor pathway.
Researchers studying retatrutide may evaluate characteristics including peptide identity, molecular mass, purity, receptor-binding behavior, structural modifications, and stability.
Detailed molecular characteristics should be referenced against primary scientific literature, manufacturer documentation, and validated analytical records rather than inferred from product appearance or labeling alone.
Retatrutide Analytical Characterization
Analytical testing can provide information about peptide identity and sample purity. Common techniques used in peptide characterization include high-performance liquid chromatography and mass spectrometry.
High-Performance Liquid Chromatography (HPLC)
High-performance liquid chromatography can be used to separate components within a peptide sample and assess the relative chromatographic purity of the material.
An HPLC result should be interpreted as one component of analytical characterization rather than as complete evidence of compound identity by itself.
Learn more about HPLC peptide purity analysis
Mass Spectrometry
Mass spectrometry can support peptide identification by measuring molecular mass characteristics and comparing experimental findings with expected molecular properties.
Using complementary analytical techniques can provide researchers with more information than relying on appearance, labeling, or a single analytical measurement.
Published Retatrutide Research
Retatrutide has been evaluated across multiple stages of clinical development.
Early Clinical Development
Early-phase research on LY3437943 evaluated pharmacokinetic, pharmacodynamic, safety, and metabolic characteristics and supported continued development of the compound.
Phase 2 Obesity Research
A randomized Phase 2 study published in the New England Journal of Medicine evaluated retatrutide in adults with obesity or overweight and investigated outcomes over 48 weeks.
Phase 2 Type 2 Diabetes Research
A Phase 2 study published in The Lancet evaluated retatrutide in participants with type 2 diabetes and examined glycemic, body-weight, and safety outcomes across different dose groups.
Phase 3 Development
Retatrutide has progressed into Phase 3 clinical development. Current and recent trials have investigated the compound in obesity, type 2 diabetes, cardiovascular disease, kidney disease, osteoarthritis, and other obesity-associated conditions.
The existence of clinical research involving retatrutide does not establish that research materials sold by third-party suppliers are intended or approved for human use.
Why Triple-Receptor Agonism Is Studied
Researchers are interested in retatrutide because it combines signaling activity at three distinct receptor systems within one investigational molecule.
Single-receptor, dual-receptor, and triple-receptor compounds provide different research models for examining how receptor combinations influence metabolic signaling and related physiological pathways.
Retatrutide therefore provides a research model that can be compared with GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists when investigating receptor-level differences.
Retatrutide Research Status
Retatrutide remains an investigational compound under clinical development. Published research and registered clinical trials should be distinguished from regulatory approval.
Researchers should consult current primary literature, regulatory sources, and clinical trial registries when evaluating the current development status of the compound.
Frequently Asked Questions About Retatrutide
What is Retatrutide?
Retatrutide is an investigational peptide developed as an agonist of the GIP, GLP-1, and glucagon receptors.
What is another name for Retatrutide?
Retatrutide has been studied under the development identifier LY3437943.
What is the CAS number for Retatrutide?
Retatrutide is commonly identified by CAS number 2381089-83-2.
What receptors does Retatrutide target?
Retatrutide is characterized by agonist activity at the GIP receptor, GLP-1 receptor, and glucagon receptor.
How is Retatrutide different from Tirzepatide?
Tirzepatide is classified as a dual GIP/GLP-1 receptor agonist, whereas retatrutide incorporates GIP, GLP-1, and glucagon receptor agonism.
How is Retatrutide different from Semaglutide?
Semaglutide primarily acts as a GLP-1 receptor agonist. Retatrutide has a triple-receptor profile involving GIP, GLP-1, and glucagon receptors.
Is Retatrutide FDA approved?
Retatrutide remains an investigational compound under clinical development and should not be represented as an FDA-approved medication.
What analytical methods are commonly used to characterize research peptides?
Methods can include high-performance liquid chromatography and mass spectrometry. The specific methods and results for an individual sample should be documented in the corresponding analytical records or Certificate of Analysis.
Inside Sciences Retatrutide Research Material
Inside Sciences provides Retatrutide 10mg as a laboratory research material together with available product specifications and batch-specific analytical documentation.
View Inside Sciences Retatrutide 10mg Research Peptide →
https://insidesciences.com/product/retatrutide-10mg-research-peptide-inside-sciences/
Related Research Resources
- GLP-1 & Multi-Receptor Research
- Retatrutide vs. Tirzepatide
- Retatrutide vs. Semaglutide
- Semaglutide vs. Tirzepatide vs. Retatrutide
- Understanding HPLC Peptide Purity Analysis
Retatrutide Research References
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972.
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023.
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022.
Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise: TRANSCEND-T2D-1. The Lancet. 2026.
Researchers should consult the original peer-reviewed publications and current clinical trial records for complete methodology, study populations, results, limitations, and safety findings.
Research Information Disclaimer: This page is provided for scientific and informational purposes. It does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or administration guidance. Retatrutide remains an investigational compound.